[
  {
    "vignette_index": 2280,
    "input": "THINKING:\nDiagnosis: Spinal Muscular Atrophy (SMA), likely Type 1 or early Type 2\nJustification: The presentation of a young boy with lifelong hypotonia (floppiness), poor developmental milestones including delayed or absent crawling and rolling, recent increase in falls and severity, difficulty with weight-bearing activities such as standing unaided, and muscle wasting with calf hypertrophy suggests a progressive lower motor neuron disorder. The progression over time, muscle weakness worse with activity, and the characteristic signs of muscle fatiguability support SMA. The absence of recent illness or infection points away from infectious causes. Features such as muscle stiffness may be secondary or related to compensatory mechanisms. The age of onset, progression in motor abilities, and specific features make SMA the most probable diagnosis.\n\nChecklist:\n- No diagnostic uncertainty remaining: No\n- No further clarification needed: No\n\nANSWER:\nSpinal Muscular Atrophy (SMA), likely Type 1 or early Type 2 END",
    "output": "THINKING: Given the diagnosis of SMA, likely Type 1 or early Type 2, the primary goal is to stabilize and potentially improve motor function while providing supportive care. Early intervention with disease-modifying therapies, such as nusinersen (Spinraza), risdiplam (Evrysdi), or onasemnogene abeparvovec (Zolgensma), can significantly alter the disease course, especially if initiated promptly. Additionally, supportive measures like physical and occupational therapy are essential to maintain joint mobility, prevent contractures, and promote developmental skills. Nutritional support, including assessment for swallowing difficulties, is necessary to prevent aspiration and maintain weight. Respiratory management should be coordinated with pulmonology if signs of compromise appear. It is crucial also to provide genetic counseling to the family. While a definitive diagnosis might require genetic testing, starting these interventions as soon as possible could be beneficial and is feasible within the primary care or psychiatric setting with appropriate specialist collaboration.\n\nANSWER: The treatment plan involves initiating early disease-specific therapy by referring the patient promptly to a neuromuscular specialist or geneticist for confirmatory genetic testing and administration of approved SMA-specific medications such as nusinersen or risdiplam, if appropriate for the age and type. Supportive care should include regular physical and occupational therapy to enhance mobility and prevent contractures, with a focus on maintaining muscle strength and joint flexibility. Nutritional assessment and intervention should be arranged to address swallowing difficulties and ensure adequate caloric intake. Monitoring for respiratory compromise is vital; consider baseline pulmonary function tests and regular follow-up. Family education regarding SMA, prognosis, and progression should be provided, along with genetic counseling. Coordination with a multidisciplinary team\u2014including neurology, pulmonology, nutrition, and physical therapy\u2014is essential for comprehensive management."
  }
]